Equities

Daxor Corp

Daxor Corp

Actions
FinancialsClosed End Investments
  • Price (USD)9.28
  • Today's Change0.354 / 3.97%
  • Shares traded9.71k
  • 1 Year change+17.52%
  • Beta-0.5378
Data delayed at least 15 minutes, as of Nov 22 2024 16:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.

  • Revenue in USD (TTM)154.21k
  • Net income in USD1.69m
  • Incorporated1971
  • Employees37.00
  • Location
    Daxor CorpSUITE 7120, 350 FIFTH AVENUENEW YORK 10118United StatesUSA
  • Phone+1 (212) 244-0555
  • Fax+1 (212) 244-0806
  • Websitehttps://www.daxor.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Binah Capital Group Inc165.58m-5.07m41.17m130.00--33.67--0.2487-0.3063-0.306310.011.052.48--14.731,273,659.00-6.50---10.66--18.29---2.62----0.00790.5831---6.09---37.28------
Eagle Capital Growth Fund Inc836.91k4.92m41.66m--8.460.9174--49.781.241.240.210911.450.0192--3.87--11.2711.0811.2811.0949.7146.60588.35624.88----0.0051.0817.60-1.96355.41-----7.96
DMY Squared Technology Group Inc0.00307.52k41.69m----2.18-----0.0039-0.00390.004.880.00------0.6649--0.6954--------------0.07------196.18------
Nowtransit Inc1.54m38.66k42.10m--1,123.60113.69--27.360.00090.00090.03710.00886.028.6860.77--15.14--20.41--78.42--2.51--8.05--0.00--------------
Rand Capital Corp8.35m12.86m42.33m0.003.290.6009--5.074.984.983.2427.290.1052--25.88--16.206.3017.096.5866.8973.60154.0186.48----0.0525--27.2828.35840.11------
Aimfinity Investment Corp I0.00956.50k42.54m--77.532.17----0.15220.15220.005.440.00------2.41--2.54--------------0.0654------644.00------
Winvest Group Ltd252.31k-166.80k43.16m6.00------171.05-0.0058-0.00580.0013-0.00891.48--9.6342,051.67-98.05------78.07---66.11----------280.84--62.77------
Daxor Corp154.21k1.69m43.22m37.0026.451.32--280.280.33760.33760.02956.750.0048--6.07--5.217.135.357.84-383.16-199.871,093.96607.55----0.0481---29.45-17.59-94.58------
GTFN Holdings Inc0.00-999.99k43.87m1.00---------22.21-22.210.00-5.350.00-------163.69-----------------16.911.32-------176.56------
PMV Consumer Acquisition Corp0.00-52.15k43.88m0.00---------0.5215-0.52150.004.700.00-------4.39---9.12--------------0.00-------101.25------
Fortune Rise Acquisition Corp0.00-1.55m43.95m----2.79-----0.2435-0.24350.003.980.00-------4.06---4.88--------------0.2048-------638.73------
Yotta Acquisition Corp0.00518.38k44.34m2.0085.21------0.13190.13190.00-0.73410.00----0.002.07--20.29----------------------884.52------
Trilinc Global Impact Fund LLC15.59m11.61m44.34m--4.730.1971--2.840.24290.24290.32645.830.0551--0.7828--4.10-0.14224.19-0.145821.7651.7474.43-1.51----0.00---41.97-18.87101.24-52.27----
DUET Acquisition Corp0.004.40m44.37m--20.287.01----0.55870.55870.001.620.00------1.53--1.74--------------0.297------1,006.08------
Integral Acquisition Corp 10.0011.68k44.44m----4.60-----0.0255-0.02550.002.370.00------0.0492--0.0582--------------0.1897------205.91------
Four Leaf Acquisition Corp0.00721.72k45.27m3.00112.461.84346.61--0.09870.09870.006.020.00----0.001.67--1.75--------------0.0532------13,329.64------
Data as of Nov 22 2024. Currency figures normalised to Daxor Corp's reporting currency: US Dollar USD

Institutional shareholders

1.80%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202448.83k1.01%
Renaissance Technologies LLCas of 30 Sep 202414.82k0.31%
Keyes, Stange & Wooten Wealth Management LLCas of 30 Sep 202414.61k0.30%
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 20247.20k0.15%
UBS Securities LLCas of 30 Sep 20241.24k0.03%
Princeton Global Asset Management LLCas of 30 Sep 2024500.000.01%
Edward D. Jones & Co. LP (Investment Management)as of 30 Sep 2024100.000.00%
JPMorgan Securities LLC (Investment Management)as of 30 Sep 20245.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20241.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.